AstraZeneca: Combination Therapy Extends Lung Cancer Survival by 5 Months
Global pharmaceutical giant AstraZeneca announced at the European Society for Medical Oncology annual meeting that combining the targeted cancer drugs osimertinib and savolitinib extends overall survival by roughly five months ... Read More